A number of inhibitors targeting SCL13A5 and ACLY have been developed as potential therapeutic agents against different malignant tumours of the brain and peripheral tissues, limiting cytoplasmic acetyl-CoA synthesis [148,152] (Table 1). The gene discussed is ACLY; the disease is cancer.